Blocking one tumor protein first may help chemo work better
Original title: Sequential EGFR inhibition sensitizes glioblastoma to temozolomide.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This is early lab work, not something a doctor can offer today.
The short version
Giving one drug before chemo may help the chemo hit brain tumor cells harder.
What was studied. Researchers looked at glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary, a serious brain cancer. They tested blocking a protein called EGFR before giving the chemo drug temozolomide.
What they found. glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary cells often make a repair protein called MGMT. MGMT fixes the damage the chemo does, so the chemo works less well. Blocking EGFR first turned down MGMT. In these tests, that made the chemo work better.
What this means, and what it doesn't
What it could mean: This points to a new way to use a chemo drug doctors already have. The idea is to give the drugs in a set order. For now this is only an early lab finding.
What it doesn't mean: This does not mean a new treatment is ready. It is early lab research, far from everyday care. No one has shown yet that this drug order helps people live longer or feel better. It is not a cure, and it is not a promise of one.
Source: PubMed, August 17, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.